Morningstar

Catalent Inc CTLT

Morningstar Rating
Unlock
Stock XNYS Rating as of
$60.33 +0.04 (0.07%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Catalent Earnings: Robust Non-Covid-19 Sales; Novo Holdings Acquisition Remains on Track to Close

Rachel Elfman

Catalent reported strong fiscal-year 2024 results, highlighted by fourth-quarter revenue of $1.3 billion, representing a 23% increase compared with the prior-year period. Non-covid-19 revenue grew by nearly 30% in the fourth quarter thanks to robust demand across the biologics segment. Fourth-quarter fiscal 2024 adjusted EBITDA was $305 million, or 23% of net revenue, compared with $122 million, or 12% of net revenue, in the fourth quarter a year ago. Catalent’s rebounding performance underscores our positive view of the company’s drug manufacturing services.

Read Full Report

Price vs Fair Value

View History
CTLT is trading at a 723% premium.
Price
$60.33
Fair Value
$36.30
Uncertainty
High
1-Star Price
$67.26
5-Star Price
$83.70
Economic Moat
Brywmdh
Capital Allocation
Gnjlpjng

Bulls Say, Bears Say

Bulls

Contract development and manufacturing organizations like Catalent have sticky businesses thanks to their customers' long-term contracts and high switching costs.

Bears

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or closures.

Show More

News

View All

Trading Information

Previous Close Price
$60.29
Day Range
$60.08–60.37
52-Week Range
$31.80–61.20
Bid/Ask
$59.42 / $60.81
Market Cap
$10.95 Bil
Volume/Avg
1.6 Mil / 1.9 Mil

Key Statistics

Price/Earnings (Normalized)
241.28
Price/Sales
2.49
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Core
Total Number of Employees
16,900
Website
https://www.catalent.com

Competitors

Valuation

View More
Metric
CTLT
LONN
ICLR
Price/Earnings (Normalized)
 241.2833.4120.38
Price/Book Value
 3.034.152.47
Price/Sales
 2.495.822.85
Price/Cash Flow
 33.0929.2516.85
Price/Earnings
CTLT
LONN
ICLR

Financial Strength

Metric
CTLT
LONN
ICLR
Quick Ratio
 1.561.381.26
Current Ratio
 2.512.041.31
Interest Coverage
 −4.076.883.75
Quick Ratio
CTLT
LONN
ICLR

Profitability

Metric
CTLT
LONN
ICLR
Return on Assets (Normalized)
 0.39%5.18%5.21%
Return on Equity (Normalized)
 1.01%9.32%9.63%
Return on Invested Capital (Normalized)
 2.72%7.38%8.65%
Return on Assets
CTLT
LONN
ICLR

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
SrrrvqrtlvZpcdz$88.3 Bil
 Merck KGaA ADR
MKKGY
GyqwqqmshJyxqvb$78.0 Bil
 Haleon PLC ADR
HLN
KnbxdhcvnVrv$48.4 Bil
 Viatris Inc
VTRS
ShykcppBydb$13.8 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
VcnympcKrxn$13.5 Bil
 Prestige Consumer Healthcare Inc
PBH
CnljtldqTjdky$3.5 Bil
 Perrigo Co PLC
PRGO
KrkxxcpFvj$3.5 Bil
 Green Thumb Industries Inc
GTBIF
NrnmgdvgyTdxwm$2.5 Bil
 Curaleaf Holdings Inc
CURLF
PmfxkkmkLrzvt$2.3 Bil

Sponsor Center